BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Treatment
48 results:

  • 1. Pyroptosis-Related Subtypes Predict the Response of Clear Cell Renal Cell Carcinoma to Targeted Therapy.
    Ma J; Kang Z; Yang G; Wang X; Si M; Wang Y; Li G; Bai S; Zeng F; Li M; Wang Z; Wang L; Xu W
    Front Biosci (Landmark Ed); 2023 Dec; 28(12):334. PubMed ID: 38179741
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
    Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
    Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. TIGIT may Serve as a Potential Target for the Immunotherapy of Renal Cell Carcinoma.
    Hong X; Yu C; Bi J; Liu Q; Wang Q
    Adv Biol (Weinh); 2024 Jan; 8(1):e2300050. PubMed ID: 37690824
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab.
    Lyu C; Stadlbauer B; Wang L; Buchner A; Pohla H
    Front Immunol; 2023; 14():1186388. PubMed ID: 37622107
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Identification of an immunogenic cell death-related gene signature predicts survival and sensitivity to immunotherapy in clear cell renal carcinoma.
    Zhou S; Lu Y; Chen Y; Gan W
    Sci Rep; 2023 Mar; 13(1):4449. PubMed ID: 36932108
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Depletion of Mannose Receptor-Positive Tumor-associated Macrophages via a Peptide-targeted Star-shaped Polyglutamate Inhibits Breast Cancer Progression in Mice.
    Lepland A; Malfanti A; Haljasorg U; Asciutto EK; Pickholz M; Bringas M; Đorđević S; Salumäe L; Peterson P; Teesalu T; Vicent MJ; Scodeller P
    Cancer Res Commun; 2022 Jun; 2(6):533-551. PubMed ID: 36923553
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Identification and experimental validation of a tumor-infiltrating lymphocytes-related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma.
    Deng Y; Guo K; Tang Z; Feng Y; Cai S; Ye J; Xi Y; Li J; Liu R; Cai C; Tan Z; Zhang Y; Han Z; Zeng G; Zhong W
    Front Immunol; 2022; 13():1046790. PubMed ID: 36505457
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma.
    Murakami T; Tanaka N; Takamatsu K; Hakozaki K; Fukumoto K; Masuda T; Mikami S; Shinojima T; Kakimi K; Tsunoda T; Sawada K; Imamura T; Mizuno R; Oya M
    Cancer Immunol Immunother; 2021 Oct; 70(10):3001-3013. PubMed ID: 34259900
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Identification of an immune overdrive high-risk subpopulation with aberrant expression of foxp3 and CTLA4 in colorectal cancer.
    Cui K; Yao S; Zhang H; Zhou M; Liu B; Cao Y; Fei B; Huang S; Huang Z
    Oncogene; 2021 Mar; 40(11):2130-2145. PubMed ID: 33627780
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Intratumoral CXCL13
    Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases.
    Steindl A; Alpar D; Heller G; Mair MJ; Gatterbauer B; Dieckmann K; Widhalm G; Hainfellner JA; Schmidinger M; Bock C; Müllauer L; Preusser M; Berghoff AS
    ESMO Open; 2021 Apr; 6(2):100057. PubMed ID: 33588158
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response.
    Hajiran A; Chakiryan N; Aydin AM; Zemp L; Nguyen J; Laborde JM; Chahoud J; Spiess PE; Zaman S; Falasiri S; Fournier M; Teer JK; Dhillon J; McCarthy S; Moran-Segura C; Katende EN; Sexton WJ; Koomen JM; Mulé J; Kim Y; Manley B
    Clin Exp Immunol; 2021 Apr; 204(1):96-106. PubMed ID: 33346915
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Human Tumor-Infiltrating MAIT Cells Display Hallmarks of Bacterial Antigen Recognition in Colorectal Cancer.
    Li S; Simoni Y; Becht E; Loh CY; Li N; Lachance D; Koo SL; Lim TP; Tan EKW; Mathew R; Nguyen A; Golovato J; Berkson JD; Prlic M; Lee B; Minot SS; Nagarajan N; Dey N; Tan DSW; Tan IB; Newell EW
    Cell Rep Med; 2020 Jun; 1(3):100039. PubMed ID: 33205061
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
    Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma.
    Kato T; Tomiyama E; Koh Y; Matsushita M; Hayashi Y; Nakano K; Ishizuya YU; Wang C; Hatano K; Kawashima A; Ujike T; Kawasaki K; Morii E; Gotoh K; Eguchi H; Kiyotani K; Fujita K; Nonomura N; Uemura M
    Anticancer Res; 2020 Sep; 40(9):4875-4883. PubMed ID: 32878775
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Obesity induces limited changes to systemic and local immune profiles in treatment-naive human clear cell renal cell carcinoma.
    Gibson JT; Norris KE; Wald G; Buchta Rosean CM; Thomas LJ; Boi SK; Bertrand LA; Bing M; Gordetsky JB; Deshane J; Li P; Brown JA; Nepple KG; Norian LA
    PLoS One; 2020; 15(5):e0233795. PubMed ID: 32469992
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma.
    Jikuya R; Kishida T; Sakaguchi M; Yokose T; Yasui M; Hashizume A; Tatenuma T; Mizuno N; Muraoka K; Umemoto S; Kawai M; Yoshihara M; Nakamura Y; Miyagi Y; Sasada T
    Cancer Immunol Immunother; 2020 Oct; 69(10):2041-2051. PubMed ID: 32424467
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma.
    Cocks M; Chaux A; Jenson EG; Miller JA; Rodriguez Pena MDC; Tregnago AC; Taheri D; Eich ML; Sharma R; Vang R; Netto GJ
    Virchows Arch; 2020 Jul; 477(1):93-102. PubMed ID: 31993774
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. foxp3 Inhibitory Peptide P60 Increases Efficacy of Cytokine-induced Killer Cells Against Renal and Pancreatic Cancer Cells.
    Setiawan MF; Rudan O; Vogt A; Gonzalez-Carmona MA; Langhans B; Schmidt-Wolf R; Garofano F; Strassburg CP; Lasarte JJ; Casares N; Lozano T; Weiher H; Schmidt-Wolf IGH
    Anticancer Res; 2019 Oct; 39(10):5369-5374. PubMed ID: 31570431
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.
    Huijts CM; Lougheed SM; Bodalal Z; van Herpen CM; Hamberg P; Tascilar M; Haanen JB; Verheul HM; de Gruijl TD; van der Vliet HJ;
    Cancer Immunol Immunother; 2019 Mar; 68(3):503-515. PubMed ID: 30652208
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.